Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products
{{output}}
Background and objectives: In 2010, an intravenous immunoglobulin (IVIG) product was removed from the market due to an association with serious thromboembolic events. Investigations revealed that factor XIa (FXIa) was present as ... ...
